Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 334

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 334
---
 registered under the registration                                                                
 statement of which this prospectus forms a part are sold in this offering, and that none of the Selling Shareholders acquire additional 
 Ordinary Shares after the date of this prospectus and prior to completion of this offering.                                             |

| (3) | Applicable percentage ownership is based on 6,685,918,922 of our 
 Ordinary Shares outstanding as of January 15, 2024.              |

| (4) | The business address of C/M Capital Master Fund, LP is 1111 Brickell Avenue, Suite 2920, Miami, Florida                                  
 33131. As of the date of the Purchase Agreement, C/M Capital Master Fund, LP did not beneficially own any shares of our common stock.    
 Thomas Walsh and Jonathan Juchno, the Managing Partners of C/M Capital Master Fund, LP, are deemed to be beneficial owners of all of the 
 shares of common stock owned by C/M Capital Master Fund, LP. Messrs. Walsh and Juchno have shared voting and investment power over the   
 shares being offered hereunder in connection with the transactions contemplated under the Purchase Agreement. C/M Capital Master Fund,   
 LP is not a registered broker-dealer or an affiliate of a registered broker-dealer.                                                      |

| 167 |

<div align='center'>PLAN OF DISTRIBUTION</div>

The securities offered by this prospectus are being
offered by the Selling Shareholder. The shares may be sold or distributed from time to time by the Selling Shareholder directly to one
or more purchasers or through brokers, dealers, or underwriters who may act solely as agents at market prices prevailing at the time of
sale, at prices related to the prevailing market prices, at negotiated prices, or at fixed prices, which may be changed. The sale of our
common stock offered by this prospectus could be effected in one or more of the following methods:

| · | ordinary brokerage transactions; |

| · | transactions involving cross or block trades; |

| · | through brokers, dealers, or underwriters who may act solely as agents; |

| · | “at the market” into an existing market for our securities; |

| · | in other ways not involving market makers or established business markets, including direct sales to purchasers or sales effected 
 through agents;                                                                                                                   |

| · | in privately negotiated transactions; or |

| · | any combination of the foregoing. |

In order to comply with the
securities laws of certain states, if applicable